Compare Boston Scientific Corporation (BSX) vs Lithium Americas Corp (LAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Lithium Americas Corp — how do they compare? Boston Scientific Corporation trades at $42.27 (market cap $66.37B), while Lithium Americas Corp trades at $3.14 (market cap $1.11B). The key difference: Boston Scientific Corporation is far larger — about 59.8× Lithium Americas Corp's market cap. Which is the better fit depends on your goals.
| BSX | LAC | |
|---|---|---|
Market Cap | $66.37B | $1.11B |
Sector | Health | Basic Materials |
52-Week High | $108.14 | $10.05 |
52-Week Low | $42.63 | $2.55 |
Enterprise Value | $75.94B | $1.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Lithium Americas (LAC) trades at $3.14, down 5.42% on the day, reflecting ongoing market pressure despite recent earnings beats. The stock shows mixed signals with bearish technical indicators but bullish oscillators suggesting potential oversold conditions. Fundamentally, the company remains in development phase with negative profitability metrics (ROE -11.35%, net loss $122M in 2025) but maintains analyst support for its Thacker Pass lithium project development.
LAC presents a high-risk, high-reward opportunity with significant execution risk on its capital-intensive lithium project. While analyst consensus targets $6.25 (99% upside), investors face dilution risk from ongoing financing needs and operational challenges. The stock's appeal hinges on successful project development and lithium market recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
